Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In vivo response monitoring of cetuximab in metastatic colorectal cancer
2009-013279-23Phase 2Completed
- Sponsor
- Heidelberg University Hospital
- Start
- Feb 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in metastatic colorectal adenocarcinoma (mCRC), sponsored by Heidelberg University Hospital. Primary endpoints: Clinical response by RECIST at day 56 and Prognostic value of early SUV change. Started Feb 2010; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2009-013279-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013279-23.